Skip to main content

Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter Results on October 19, 2022

Elevance Health (NYSE: ELV) will release third quarter 2022 financial results on October 19, 2022, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:

888-947-9963 (Domestic)

800-813-5525 (Domestic Replay)

312-470-0178 (International)

203-369-3346 (International Replay)

The access code for the call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EDT on October 19, 2022 until the end of the day on November 18, 2022. The call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. A webcast replay will be available following the call.

About Elevance Health, Inc.

Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s companies serve more than 118 million people through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on Twitter and Elevance Health on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.27
+5.41 (2.64%)
AAPL  264.38
+3.80 (1.46%)
AMD  201.35
-2.02 (-0.99%)
BAC  52.98
+0.21 (0.40%)
GOOG  315.02
+11.46 (3.78%)
META  658.14
+13.36 (2.07%)
MSFT  398.75
+0.29 (0.07%)
NVDA  189.86
+1.96 (1.04%)
ORCL  149.28
-7.26 (-4.64%)
TSLA  413.23
+1.52 (0.37%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.